J&J adds yet an­oth­er mul­ti­ple myelo­ma reg­i­men to the Darza­lex la­bel as Sanofi ri­val jumps in

J&J’s third-line mul­ti­ple myelo­ma block­buster Darza­lex got the FDA green light for a new reg­i­men to take an­oth­er swing at the blood can­cer — this time, in a cock­tail with carfil­zomib and dex­am­etha­sone.

The com­bi­na­tion ther­a­py was ap­proved to treat re­lapsed or re­frac­to­ry mul­ti­ple myelo­ma pa­tients who have al­ready re­ceived one to three lines of treat­ment.

Darza­lex, a CD38-di­rect­ed an­ti­body, led the mar­ket for years af­ter its ap­proval in 2015 for third-line mul­ti­ple myelo­ma pa­tients. But this year, it faces com­pe­ti­tion from Sanofi’s Sar­clisa, an­oth­er CD38-tar­get­ing drug ap­proved in April as a third-line treat­ment for mul­ti­ple myelo­ma pa­tients, in com­bi­na­tion with po­ma­lido­mide and dex­am­etha­sone.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN